A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

By sjmartinez • August 2, 2024

Curigliano G, Jimenez MM, Shimizu T, Keam B, Meric-Bernstam F, Rutten A, Glaspy J, Schuler PJ, Parikh NS, Ising M, Hassounah N, Wu J, Leyk M, Chen X, Burks H, Chaudhury A, Otero J, Cabanas EG. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies. ESMO Open. 2024 Jul 31;9(8):103643. doi: 10.1016/j.esmoop.2024.103643. Epub ahead of print. PMID: 39088985.

Tags: Hematology/Oncology, Keywords: LHC165; PDR001; TLR7 agonist; advanced, LHC165, PDR001, Publications, TLR7 agonist

Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models

Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg[...]